Get the Stockscreener App
6.65
5.29%
0.32
Contineum Therapeutics Inc stock is traded at $6.65, with a volume of 93,675.
It is up +5.29% in the last 24 hours and up +74.93% over the past month.
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.
See More
Previous Close:
$6.33
Open:
$6.43
24h Volume:
93,675
Relative Volume:
0.45
Market Cap:
$128.25M
Revenue:
-
Net Income/Loss:
$-35.46M
P/E Ratio:
-15.77
EPS:
-0.4218
Net Cash Flow:
$-34.00M
1W Performance:
+12.97%
1M Performance:
+74.93%
6M Performance:
-20.75%
1Y Performance:
-60.47%
1-Day Range:
$6.32
$6.95
1-Week Range:
$5.07
$6.95
52-Week Range:
$3.35
$20.55
Contineum Therapeutics Inc Stock (CTNM) Company Profile
Name
Contineum Therapeutics Inc
Sector
Industry
Phone
(858) 333-5280
Address
3565 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO
Compare CTNM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTNM
Contineum Therapeutics Inc
|
6.70 | 155.23M | 0 | -35.46M | -34.00M | -0.4218 |
|
VRTX
Vertex Pharmaceuticals Inc
|
383.34 | 96.11B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.49 | 60.40B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.20 | 54.91B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
671.01 | 41.30B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
295.05 | 33.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Contineum Therapeutics Inc Stock (CTNM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-20-25 | Initiated | William Blair | Outperform |
| Oct-22-24 | Initiated | Robert W. Baird | Outperform |
| Apr-30-24 | Initiated | Morgan Stanley | Overweight |
| Apr-30-24 | Initiated | RBC Capital Mkts | Outperform |
| Apr-30-24 | Initiated | Stifel | Buy |
Contineum Therapeutics Inc Stock (CTNM) Latest News
Why Contineum Therapeutics Inc. stock attracts strong analyst attentionFree Technical Stock Breakout Predictions - Newser
Will earnings trigger a reversal in Contineum Therapeutics Inc.Risk Adjusted Trade Signal Screening Tool - Newser
Price momentum metrics for Contineum Therapeutics Inc. explainedChart Scanner for Swing Trade Timing - Newser
Earnings visualization tools for Contineum Therapeutics Inc.Chart Confirmation Setup with ROI Signals - Newser
How Contineum Therapeutics Inc. stock reacts to Fed policy changesFree Risk Adjusted Technical Entry Plan - Newser
What makes Contineum Therapeutics Inc. stock price move sharplyTechnical Reversal Pattern Summary and Tracker - Newser
Technical signs of recovery in Contineum Therapeutics Inc.Predictive AI Engine for Smart Investing - Newser
Contineum Therapeutics Reports Second-Quarter 2025 Financial Results; Updates Key Clinical Development Milestones - BioSpace
Has Contineum Therapeutics Inc. Stock Ever Crashed Historical Volatility ReviewSecure Buy Strategy Based on Risk Parameters - Newser
Strategies to average down on Contineum Therapeutics Inc.Real-Time AI Entry Forecast Generator - Newser
What data driven models say about Contineum Therapeutics Inc.’s futureTrend Reversal Probability Forecast Update - Newser
Contineum (CTNM) Q2 R&D Jumps 78% - The Globe and Mail
Contineum (CTNM) Q2 R&D Jumps 78% - The Motley Fool
Applying Elliott Wave Theory to Contineum Therapeutics Inc.AI-Based Stock Behavior Forecast Engine - Newser
Using portfolio simulators with Contineum Therapeutics Inc. includedFree Short Term High Yield Stock Tips - Newser
Contineum Therapeutics, Inc. SEC 10-Q Report - TradingView
Contineum Therapeutics Updates Clinical Development Milestones and Reports Q2 2025 Financial Results. - AInvest
Contineum Therapeutics Inc. Stock Performance After Earnings: Historical InsightsDaily Exit and Entry Price Prediction - Newser
What drives Contineum Therapeutics Inc. stock priceHigh-yield market plays - Jammu Links News
Long term hold vs stop loss in Contineum Therapeutics Inc.Technical Trend Forecast for Investors - Newser
What machine learning models say about Contineum Therapeutics Inc.Fundamental Analysis for Value Stock Selection - Newser
What analysts say about Contineum Therapeutics Inc. stockCapitalize on emerging trends for profits - Jammu Links News
Why is Contineum Therapeutics Inc. stock attracting strong analyst attentionTremendous growth opportunities - Jammu Links News
What are analysts’ price targets for Contineum Therapeutics Inc. in the next 12 monthsBuild wealth with high-performing stocks - Jammu Links News
What are the technical indicators suggesting about Contineum Therapeutics Inc.Free Consultation - Jammu Links News
How does Contineum Therapeutics Inc. generate profit in a changing economyMaximize your gains with expert trading tips - Jammu Links News
How volatile is Contineum Therapeutics Inc. stock compared to the marketGet professional advice for portfolio optimization - Jammu Links News
When is Contineum Therapeutics Inc. stock expected to show significant growthGet professional guidance for market timing - Jammu Links News
How high can Contineum Therapeutics Inc. stock goQuarterly Investment Outlook and Key Summary - Newser
How does Contineum Therapeutics Inc. compare to its industry peersUnmatched market performance - Jammu Links News
Is Contineum Therapeutics Inc. a growth stock or a value stockUnmatched market performance - Jammu Links News
What are the latest earnings results for Contineum Therapeutics Inc.Free Daily Trading Room Entry - Jammu Links News
Visualizing Contineum Therapeutics Inc. stock with heatmapsFree Consistent Income Focused Trade List - Newser
Developing predictive dashboards with Contineum Therapeutics Inc. dataDaily Investment Ideas with Market Insight - Newser
What is the risk reward ratio of investing in Contineum Therapeutics Inc. stockMarket Forecast Alerts Backed By Experts - Jammu Links News
Contineum Therapeutics Inc Stock (CTNM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.46%
1.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):